J. Russel Denton - 22 Sep 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Reporting relationship: Senior Vice President, General Counsel, and Secretary
Issuer ticker: CAI
Reported as of: 22 Sep 2026
Net transaction value: -$238,626
SEC form: 4
Accepted by SEC: 23 Sep 2026, 17:06:43 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton

Key filing fact

J. Russel Denton filed Form 4 for Caris Life Sciences, Inc. (CAI) on 23 Sep 2026.

Key facts

This page summarizes J. Russel Denton's Form 4 filing for Caris Life Sciences, Inc. (CAI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Sep 2026, 17:06.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$238,626.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002071923 Primary reporting owner

Denton John Russel

Relationship: Senior Vice President, General Counsel, and Secretary
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton
Signature date: 23 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Sale

Transaction value: $238,626
Shares: -7,500
Change %: -4.1%
Price: $31.82
Shares after: 174,855
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1, F2

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,184
Date: 22 Sep 2026
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4.

SEC remarks

Senior Vice President, General Counsel, and Secretary